Hezhi Pharm

Hezhi Pharm is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of innovative RNA-based therapeutics. The company leverages its proprietary GalNAc-siRNA delivery technology to create long-acting treatments for chronic and rare diseases, with a primary focus on cardiovascular and metabolic health. Its lead program, HZ-A-001, is an siRNA targeting PCSK9 for hypercholesterolemia, currently in clinical development. Hezhi Pharm's pipeline also features HZ-A-002 for hypertension and other candidates targeting transthyretin amyloidosis and viral infections. The company aims to transform patient care by providing highly specific and durable nucleic acid medicines.